AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36242744 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative abundance of Akkermansia, Lachnospiraceae sp. and Ruminococcus genera
Number of subjects: 82
Study 36242744 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative abundance of Bifidobacterium genus
Number of subjects: 82
Study 36242744 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative abundance of Sutterellaceae and Bifidobacteriaceae families
Number of subjects: 82
Study 36242764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0
Study 36242764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study 36243061 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine multidisciplinary ICU recovery clinic visits
Number of subjects: 32
Study 36243111 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-EXL
Number of subjects: 1454
Study 36243111 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-Architect
Number of subjects: 1454
Study 36243111 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT-Elecsys
Number of subjects: 1454
Study 36243111 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-EXL-specific 0/1h-algorithm
Number of subjects: 1454
Study 36243199 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Number of subjects: 0
Study 36243199 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 36243263 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) monitoring of micro-embolic signals (MES) pre- and post-carotid endarterectomy
Number of subjects: 120
Study 36243263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of plaque characteristics
Number of subjects: 120
Study 36243263 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological analysis of plaque vulnerability
Number of subjects: 120
Study 36243263 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis severity assessment
Number of subjects: 120
Study 36243733 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum Humanin (HN) levels
Number of subjects: 165
Study 36243733 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum GDF15 levels
Number of subjects: 165
Study 36243733 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum FGF21 levels
Number of subjects: 165
Study 36243744 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs) measured at V1, V2, V3, and V5
Number of subjects: 41
Study 36243744 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve of HMOs from baseline to 4 months of age
Number of subjects: 41
Study 36243744 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group)
Number of subjects: 41
Study 36243812 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg (UPA15)
Number of subjects: 1704
Study 36243812 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg (UPA30)
Number of subjects: 1704
Study 36243812 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg (ADA)
Number of subjects: 1704
Study 36244405 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive QTVi during arousal
Number of subjects: 2558
Study 36244653 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 79
Study 36244653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 36244863 — intervention group
Group type: EXPERIMENTAL
Intervention: BKL angiographic pattern
Number of subjects: 389
Study 36244863 — intervention group
Group type: COMPARATOR
Intervention: Non-BKL angiographic pattern (Control)
Number of subjects: 389
Study 36244985 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Disability Index (NDI-G)
Number of subjects: 50
Study 36245008 — intervention group
Group type: EXPERIMENTAL
Intervention: IHSG wording
Number of subjects: 1430
Study 36245008 — intervention group
Group type: COMPARATOR
Intervention: PP wording
Number of subjects: 1430
Study 36245627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive warming to a target core temperature of 37 ℃
Number of subjects: 205
Study 36245627 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal management to a target of 35.5 ℃
Number of subjects: 205
Study 36245729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin measurement (≥100 μg/g)
Number of subjects: 0
Study 36245729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin measurement (<100 μg/g)
Number of subjects: 0
Study 36245743 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey-based follow-on formula (pHF-W FoF)
Number of subjects: 100
Study 36246184 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg fixed dosing every 8 weeks after initial treatment with 6 intravitreal doses at 4-week intervals
Number of subjects: 1891
Study 36246184 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg dosed according to personalized treatment interval (PTI) after initial treatment with 4 every-4-week doses
Number of subjects: 1891
Study 36246184 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg dosed every 8 weeks after 5 initial every-4-week doses
Number of subjects: 1891
Study 36246184 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg with PTI regimen (up to every-16-week adjustable dosing)
Number of subjects: 1891
Study 36246184 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg and Aflibercept 2.0 mg
Number of subjects: 1891
Study 36246814 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/d ETV (Group A)
Number of subjects: 275
Study 36246814 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV maleate (Group B)
Number of subjects: 275
Study 36246814 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 275
Study 36246941 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg up to every 16 weeks after 4 initial every-4-week doses
Number of subjects: 0
Study 36246941 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks after 3 initial every-4-week doses
Number of subjects: 0
Study 36246941 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab with personalized treatment interval (PTI)
Number of subjects: 0
Study 36247059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdentures assisted by two ultrashort implants with PBM therapy (Dose A: 3.75 J/cm²)
Number of subjects: 12
Study 36247059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdentures assisted by four ultrashort implants with PBM therapy (Dose A: 3.75 J/cm²)
Number of subjects: 12
Study 36247059 — intervention group
Group type: COMPARATOR
Intervention: PBM therapy (Dose A: 3.75 J/cm²)
Number of subjects: 12
Study 36247059 — intervention group
Group type: COMPARATOR
Intervention: PBM therapy (Dose B: not specified)
Number of subjects: 12
Study 36247444 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) using J-Valve system for 4 patients with pure aortic regurgitation and Venus-A system for 1 patient with severe aortic stenosis.
Number of subjects: 5
Study 36247452 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010 WHO guidelines (≥30 min moderate- to vigorous-intensity PA at ≥ 10-min bout duration)
Number of subjects: 282
Study 36247452 — intervention group
Group type: EXPERIMENTAL
Intervention: 2020 WHO guidelines (≥30 min of MVPA of any bout duration)
Number of subjects: 282
Study 36247452 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily steps ≥7,500
Number of subjects: 282
Study 36247452 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily steps ≥10,000
Number of subjects: 282
Study 36247455 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity trackers to monitor physical activity (PA)
Number of subjects: 0
Study 36247455 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer data collection for 18 days post-discharge and 14 days at one-year follow-up
Number of subjects: 0
Study 36247744 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC formulation containing raloxifene 60 mg and cholecalciferol 800 IU
Number of subjects: 46
Study 36247744 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of raloxifene and cholecalciferol
Number of subjects: 46
Study 36247751 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF/CITED2 ratio from peripheral blood mononuclear cells (PBMCs)
Number of subjects: 67
Study 36247751 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary logistic regression analysis
Number of subjects: 67
Study 36247749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ankle-brachial index (ABI) ≤0.9
Number of subjects: 325
Study 36247749 — intervention group
Group type: COMPARATOR
Intervention: Normal ankle-brachial index (ABI) >0.9
Number of subjects: 325
Study 36247822 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin
Number of subjects: 62
Study 36247822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 36247923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg intravenously Q2W
Number of subjects: 104
Study 36247923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 36247923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 104
Study 36247958 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperJump activity (exercise group)
Number of subjects: 24
Study 36247958 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (control group)
Number of subjects: 24
Study 36248000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction + Computerized Cognitive Training (CCT)
Number of subjects: 141
Study 36248000 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE) + Computerized Cognitive Training (CCT)
Number of subjects: 141
Study 36248000 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 141
Study 36248617 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (two doses)
Number of subjects: 378
Study 36248865 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoantigen vaccination after local RFA treatment
Number of subjects: 28
Study 36248865 — intervention group
Group type: COMPARATOR
Intervention: Neoantigen vaccination without prior RFA treatment
Number of subjects: 28
Study 36249001 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Experience (VRE)
Number of subjects: 44
Study 36249001 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 36249475 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch Series 6
Number of subjects: 24
Study 36249475 — intervention group
Group type: COMPARATOR
Intervention: Masimo Radical-7
Number of subjects: 24
Study 36249526 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (single dose)
Number of subjects: 0
Study 36249526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 36249705 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM103 (Recombinant Human Complement Factor H) at doses of 50 μg/eye, 100 μg/eye, 250 μg/eye, or 500 μg/eye
Number of subjects: 12
Study 36249765 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative duloxetine
Number of subjects: 0
Study 36249765 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 36250171 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calprotectin (fCAL) in PSC-IBD
Number of subjects: 48
Study 36250171 — intervention group
Group type: COMPARATOR
Intervention: Faecal calprotectin (fCAL) in UC
Number of subjects: 48
Study 36250171 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calprotectin (fCAL) in PSC-IBD (quiescent colitis)
Number of subjects: 48
Study 36250171 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of biliary complications in PSC-IBD
Number of subjects: 48
Study 36250171 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of fCAL with biliary calprotectin
Number of subjects: 48
Study 36250418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapies plus land-based exercise therapy
Number of subjects: 6508
Study 36250418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive electrophysical agents plus exercise
Number of subjects: 6508
Study 36250418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapies plus exercise
Number of subjects: 6508
Study 36250577 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care test
Number of subjects: 10218
Study 36250577 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin point-of-care test
Number of subjects: 10218
Study 36250577 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 10218
Study 36251174 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 1821
Study 36251211 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade adenocarcinoma patients
Number of subjects: 85
Study 36251211 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to brain metastasis
Number of subjects: 85
Study 36251211 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to non-brain metastasis
Number of subjects: 85
Study 36251211 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival after first progression (brain metastasis)
Number of subjects: 85
Study 36251211 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival after first progression (non-brain metastasis)
Number of subjects: 85
Study 36251220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab monotherapy (350 mg every 3 weeks intravenously)
Number of subjects: 295
Study 36251223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia at 33 °C
Number of subjects: 581
Study 36251223 — intervention group
Group type: COMPARATOR
Intervention: Controlled normothermia at 37 °C
Number of subjects: 581
Study 36251376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 20
Study 36251376 — intervention group
Group type: COMPARATOR
Intervention: No nutritional supplement (Control)
Number of subjects: 20
Study 36251401 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT)
Number of subjects: 384
Study 36251401 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-General (FACT-G), SF-36, EQ-5D
Number of subjects: 384
Study 36251401 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PRO scores
Number of subjects: 384
Study 36251466 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36251488 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36251503 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa) + Cemiplimab (Cemi)
Number of subjects: 58
Study 36251766 — intervention group
Group type: EXPERIMENTAL
Intervention: ORADUR-Methylphenidate, dosage and duration not available
Number of subjects: 0
Study 36251868 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary approaches
Number of subjects: 0
Study 36251868 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36252092 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion or magnetic resonance imaging selection for thrombectomy
Number of subjects: 715
Study 36252092 — intervention group
Group type: COMPARATOR
Intervention: Noncontrast CT selection for thrombectomy
Number of subjects: 715
Study 36252116 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning score integrating CCTA-based quantitative plaque features
Number of subjects: 208
Study 36252116 — intervention group
Group type: COMPARATOR
Intervention: Visual stenosis grade
Number of subjects: 208
Study 36252116 — intervention group
Group type: COMPARATOR
Intervention: Standard CCTA stenosis evaluation
Number of subjects: 208
Study 36252116 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 208
Study 36252167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1873
Study 36252167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study 36252241 — intervention group
Group type: EXPERIMENTAL
Intervention: Social distancing adherence
Number of subjects: 499
Study 36252241 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased alcohol use
Number of subjects: 499
Study 36252241 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-VAS score
Number of subjects: 499
Study 36252241 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant depressive symptoms (PHQ-9 score ≥10)
Number of subjects: 499
Study 36252241 — intervention group
Group type: EXPERIMENTAL
Intervention: Worrying about contracting COVID-19
Number of subjects: 499
Study 36252241 — intervention group
Group type: EXPERIMENTAL
Intervention: Having ≥3 comorbidities
Number of subjects: 499
Study 36252241 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding social distancing easy
Number of subjects: 499
Study 36252241 — intervention group
Group type: EXPERIMENTAL
Intervention: Age younger than 60 years
Number of subjects: 499
Study 36252397 — intervention group
Group type: EXPERIMENTAL
Intervention: M. tuberculosis H37Rv
Number of subjects: 30
Study 36252397 — intervention group
Group type: COMPARATOR
Intervention: M. bovis BCG
Number of subjects: 30
Study 36252397 — intervention group
Group type: EXPERIMENTAL
Intervention: M. tuberculosis H37Rv and M. bovis BCG
Number of subjects: 30
Study 36252414 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) diagnosis
Number of subjects: 60
Study 36252414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSA
Number of subjects: 60
Study 36252414 — intervention group
Group type: COMPARATOR
Intervention: No OSA
Number of subjects: 60
Study 36252789 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of mRNA COVID-19 vaccine
Number of subjects: 4091
Study 36252789 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of mRNA COVID-19 vaccine
Number of subjects: 4091
Study 36252805 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria in pregnancy (MIP)
Number of subjects: 307
Study 36252805 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth, low birthweight, increasing maternal education level, and increasing interleukin 6 levels
Number of subjects: 307
Study 36252805 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe neurocognitive delay
Number of subjects: 307
Study 36252870 — intervention group
Group type: EXPERIMENTAL
Intervention: ML EGD (machine learning-based model)
Number of subjects: 2794
Study 36252870 — intervention group
Group type: COMPARATOR
Intervention: Baveno VI criteria
Number of subjects: 2794
Study 36252998 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 plus pembrolizumab (3.6 mg/kg T-DM1 every 21 days plus 200 mg pembrolizumab every 21 days)
Number of subjects: 20
Study 36252998 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 plus pembrolizumab
Number of subjects: 20
Study 36253275 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial cytokines that elicit ILC2 activation
Number of subjects: 0
Study 36253275 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural signals from sympathetic, parasympathetic, sensory, and enteric fibers
Number of subjects: 0
Study 36253275 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-epithelial-ILC2 crosstalk
Number of subjects: 0
Study 36253275 — intervention group
Group type: EXPERIMENTAL
Intervention: Disturbed ILC2-centered neuro-epithelial-immune cell interactions
Number of subjects: 0
Study 36253296 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital ECG interpretation
Number of subjects: 2122
Study 36253296 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert interpretation of serial ECG changes
Number of subjects: 2122
Study 36253296 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-augmented out-of-hospital ECG
Number of subjects: 2122
Study 36253296 — intervention group
Group type: COMPARATOR
Intervention: ED ECG interpretation
Number of subjects: 2122
Study 36253295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-ED care
Number of subjects: 1191
Study 36253295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-ED care (subgroup of advanced practice providers)
Number of subjects: 1191
Study 36253484 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 20
Study 36253663 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-[
Number of subjects: 24
Study 36253829 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a ventilation tube into the tympanic membrane
Number of subjects: 104
Study 36253829 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 104
Study 36253834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco dependence treatment (TDT) intervention counseling
Number of subjects: 16
Study 36253834 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies (training and system changes)
Number of subjects: 16
Study 36253834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study intervention
Number of subjects: 16
Study 36253875 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment and standardized treatment
Number of subjects: 3241
Study 36253875 — intervention group
Group type: COMPARATOR
Intervention: Microsurgery
Number of subjects: 3241
Study 36253875 — intervention group
Group type: COMPARATOR
Intervention: Embolization
Number of subjects: 3241
Study 36253875 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 3241
Study 36253875 — intervention group
Group type: COMPARATOR
Intervention: Combination of embolization and SRS
Number of subjects: 3241
Study 36253875 — intervention group
Group type: COMPARATOR
Intervention: Conservation
Number of subjects: 3241
Study 36253875 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 3241
Study 36253882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 89
Study 36253968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ω-3 index (≤3.70%)
Number of subjects: 832